Testing HARPP for PTSD and Obesity in Veterans
This study is testing an integrated treatment called HARPP for Veterans who have both Post-Traumatic Stress Disorder (PTSD) and obesity. HARPP combines a weight management program (MOVE!) with a type of therapy for PTSD called Cognitive Processing Therapy (CPT). Researchers want to see if HARPP is more effective at helping Veterans lose weight and reduce their PTSD symptoms compared to standard care, which involves separate referrals to MOVE! and CPT. The study plans to enroll 182 adult Veterans who have a current PTSD diagnosis and a BMI of 30 kg/m2 or higher. Success will be measured by changes in weight and PTSD symptom severity after 12 months. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 182 adult Veterans. Participants will be assigned to either receive the HARPP intervention or a control arm receiving standard care.
- What's involved
- Participants will receive up to 16 individual psychotherapy sessions as part of the HARPP intervention or standard CPT sessions in the control group. Weight and PTSD symptoms will be measured at 12 months after starting the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months after starting the study to measure changes in weight and PTSD symptoms.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Katherine D Hoerster, PhD MPH BA · PRINCIPAL_INVESTIGATOR · VA Puget Sound Health Care System Seattle Division, Seattle, WA
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- 12-month absolute weight change in pounds12 months post-baseline
Body weight will be measured on a study scale at baseline and 12 months following baseline. This study's co-primary aim is to test whether intervention participants have greater 12-month weight loss, relative to controls.
- 12-month absolute PTSD symptom severity change12 months post-baseline
PTSD symptom severity will be measured via self-report on the PTSD Checklist for DSM-5 at baseline and 12 months following baseline. This study's co-primary aim is to test whether intervention participants have greater 12-month PTSD symptom reduction, relative to controls.